

PHARMACY COVERAGE GUIDELINE

NUEDEXTA™ (dextromethorphan and quinidine) Generic Equivalent (if available)

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and/or Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
- Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.

Medical Necessity Requirements for NUEDEXTA (dextromethorphan and quinidine)

Criteria for Initial Therapy:

Indication

- Pseudobulbar Affect associated with a chronic neurological condition such as:
 - Amyotrophic lateral sclerosis
 - Multiple sclerosis
 - Stroke
 - Dementia
 - Traumatic brain injury

PHARMACY COVERAGE GUIDELINE

NUEDEXTA™ (dextromethorphan and quinidine) Generic Equivalent (if available)

- Symptoms include involuntary, sudden, and frequent episodes of laughing and/or crying that are out of proportion or incongruent to the underlying emotional state

Age Requirement

- 18 years or older

Baseline Clinical Evaluation

- Center for Neurologic Studies Liability Scale (CNS-LS) score of 13 or more
- Completed baseline tests:
 - Serum potassium and magnesium (corrected if abnormal)
 - Electrocardiogram for individuals at risk for QT prolongation and torsade de pointes (e.g., bradycardia, family history of QT abnormality, left ventricular hypertrophy or dysfunction)

Alternative Therapies

- Failure (trial for at least three months duration), contraindication, intolerance to **TWO** of the following:
 - Either amitriptyline or nortriptyline
 - Fluoxetine
 - Fluvoxamine
 - Sertraline

Brand Specific Criteria

- Have failure, contraindication, or intolerance with **THREE** generic equivalents (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- No concomitant use with:
 - Quinidine
 - Quinine
 - Mefloquine
- No history of:
 - Quinidine, Quinine, or Mefloquine-induced thrombocytopenia, hepatitis, bone marrow depression, lupus-like syndrome, or hypersensitivity reaction
 - Hypersensitivity to dextromethorphan (e.g., rash or hives)
- No use with monoamine oxidase inhibitor (MAOI) or within 14 days of starting/stopping MAOI
- No prolonged QT interval, congenital long QT syndrome, history of torsades de pointes, or heart failure
- No complete atrioventricular node block without an implanted pacemaker or high risk of complete AV block
- No use with drugs that both prolong QT interval and are metabolized by cytochrome P450 2D6 (e.g., thioridazine or pimozide)
- Will not be used with another dextromethorphan-containing product for other medical condition
- No severe renal impairment

ORIGINAL EFFECTIVE DATE: 09/08/2011 | ARCHIVE DATE: | LAST REVIEW DATE: 05/15/2025 | LAST CRITERIA REVISION DATE: 05/15/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

NUEDEXTA™ (dextromethorphan and quinidine) Generic Equivalent (if available)

- No severe hepatic impairment

Documentation Requirements

- A completed request form must be submitted, including
 - Chart notes
 - Lab results (serum potassium, magnesium, electrocardiogram)
 - Supporting clinical documentation

Initial Therapy Criteria Approval Duration:

- 6 months OR end of plan year
-

Criteria for Continuation of Therapy (renewal therapy)

Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy

Clinical Response

- Achieved and maintains at least **ONE** of the following:
 - 30% reduction in Center for Neurologic Studies Liability Scale (CNS-LS) over baseline
 - 30% reduction in frequency of laughing and crying episodes that are out of proportion or incongruent to the underlying emotional state

Adherence

- Adherence to the prescribed therapy regimen has been documented

Brand Specific Criteria

- Have failure, contraindication, or intolerance with **THREE** generic equivalents (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- No new contraindications or significant adverse drug effects such as:
 - Immune-mediated drug-induced thrombocytopenia
 - Hepatitis
 - Serotonin syndrome
 - Torsades de point-type ventricular arrhythmia
- Will not be used with another dextromethorphan-containing product for other medical condition
- No severe renal impairment
- No severe hepatic impairment

Documentation Requirements

- Chart notes
- Supporting clinical documentation with evidence of improvement in pseudobulbar affect
- Lab values that confirm safe use

ORIGINAL EFFECTIVE DATE: 09/08/2011 | ARCHIVE DATE: | LAST REVIEW DATE: 05/15/2025 | LAST CRITERIA REVISION DATE: 05/15/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

NUEDEXTA™ (dextromethorphan and quinidine) Generic Equivalent (if available)

Continuation Therapy Criteria Approval Duration:

- 12 months OR end of plan year
-

Criteria for Off-Label Use Requests:

Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. Off-Label Use of Non-Cancer Medications
 2. Off-Label Use of Cancer Medications
-

Description:

Nuedexa (dextromethorphan and quinidine) is the first and only FDA-approved treatment for pseudobulbar affect (PBA). PBA is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying that are out of proportion or incongruent to the underlying emotional state. PBA occurs as a secondary presentation to a variety of unrelated neurological conditions. It is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury.

Nuedexa capsules contain 20mg of dextromethorphan hydrobromide and 10mg of quinidine sulfate. Dextromethorphan, found in many cough medicines, is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. Its mechanism of action as an antitussive agent occurs through depression of the medullary cough center, interruption of cough impulse transmission, and a reduction of the sensitivity of cough reflex. The mechanism by which dextromethorphan exerts therapeutic effects in PBA is unknown. Quinidine is a class 1A anti-arrhythmic used in individuals with atrial fibrillation. In Nuedexa (dextromethorphan and quinidine), its purpose is to inhibit metabolism of dextromethorphan via CYP2D6, leading to higher levels plasma levels of dextromethorphan.

Nuedexa (dextromethorphan and quinidine) is contraindicated in individuals with a history of Nuedexa (dextromethorphan and quinidine), quinine, mefloquine or quinidine-induced thrombocytopenia, hepatitis, bone marrow depression or lupus-like syndrome. Nuedexa (dextromethorphan and quinidine) is also contraindicated in individuals with a known hypersensitivity to dextromethorphan (e.g., rash, hives). The safety and effectiveness of Nuedexa (dextromethorphan and quinidine) in pediatric individuals below the age of 18 have not been established.

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

Center for Neurologic Studies Liability Scale (CNS-LS):

- A seven-item self-report questionnaire with 3 items assessing crying and 4 assessing laughter

ORIGINAL EFFECTIVE DATE: 09/08/2011 | ARCHIVE DATE: | LAST REVIEW DATE: 05/15/2025 | LAST CRITERIA REVISION DATE: 05/15/2025

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

NUEDEXTA™ (dextromethorphan and quinidine) Generic Equivalent (if available)

- A score of 13 or more may suggest PBA
- The CNS-LS has been validated in ALS and MS patients

Center for Neurologic Studies Lability Scale (CNS-LS)					
Using the scale below, write the number that describes the degree to which each item applies to you during the past week. Write only one number for each item					
Never applies	Rarely applies	Occasionally applies	Frequently applies	Applies most of the time	
1	2	2	4	4	
					Degree
There are times when I feel fine one minute, and then I'll become tearful the next over something small or for no reason at all					
Others have told me that I seem to become amused very easily or that I seem to become amused about things that are not funny					
I find myself crying very easily					
I find that even when I try to control my laughter, I am often unable to do so					
There are times when I won't be thinking of anything happy or funny at all, but then I'll suddenly be overcome by funny or happy thoughts					
I find that even when I try to control my crying, I am often unable to do so					
I find that I am easily overcome by laughter					
Total					

Resources:

Nuedexa (dextromethorphan and quinidine) product information, revised by Otsuka America Pharmaceuticals, Inc. 12-2022. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed February 18, 2025.

Galvez-Jimenez N. Quinn C. Symptom-based management of amyotrophic lateral sclerosis. In: UpToDate, Shefner JM, Morrison S, Goddeau RP (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through February 2025. Topic last updated September 05, 2024. Accessed March 06, 2025.

Press D. Management of neuropsychiatric symptoms of dementia. In: UpToDate, DeKosky ST, Schmader KE, Mendez, MF, Wilterdink JL (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through February 2025. Topic last updated April 07, 2022. Accessed March 06, 2025.